Compare · LEGN vs SQZ
LEGN vs SQZ
Side-by-side comparison of Legend Biotech Corporation (LEGN) and SQZ Biotechnologies Company (SQZ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. LEGN focuses on Biotechnology: Pharmaceutical Preparations, while SQZ focuses on Medicinal Chemicals and Botanical Products .
- LEGN is the larger of the two at $3.70B, about 19.9x SQZ ($185.8M).
- LEGN has hit the wire 17 times in the past 4 weeks while SQZ has been quiet.
- LEGN has more recent analyst coverage (25 ratings vs 0 for SQZ).
- Company
- Legend Biotech Corporation
- SQZ Biotechnologies Company
- Price
- $18.79-5.03%
- $0.44+59.83%
- Market cap
- $3.70B
- $185.8M
- 1M return
- +6.85%
- -
- 1Y return
- -41.87%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- 2020
- News (4w)
- 17
- 0
- Recent ratings
- 25
- 0
Legend Biotech Corporation
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in North America and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in relapsed and refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins lymphoma (NHL), acute myeloid leukemia, and T cell lymphoma. In addition, it is developing allogeneic CAR-T product candidates targeting CD20 for the treatment of NHL and targeting B-cell maturation antigen for the treatment of MM, which are currently in an investigator-initiated Phase 1 clinical trial in China. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
SQZ Biotechnologies Company
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Latest LEGN
- SEC Form 6-K filed by Legend Biotech Corporation
- Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
- SEC Form 6-K filed by Legend Biotech Corporation
- SEC Form S-8 filed by Legend Biotech Corporation
- Director Sanders Corazon (Corsee) D. sold $258,920 worth of Ordinary Shares (27,370 units at $9.46), decreasing direct ownership by 34% to 52,731 units (SEC Form 4)
- Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
- SEC Form 144 filed by Legend Biotech Corporation
- Director Heyman Tomas J. was granted 20,986 units of Ordinary Shares, increasing direct ownership by 64% to 53,720 units (SEC Form 4)
- Director Casey Patrick John was granted 20,986 units of Ordinary Shares, increasing direct ownership by 43% to 69,590 units (SEC Form 4)
- Director Mao Li was granted 20,986 units of Ordinary Shares, increasing direct ownership by 47% to 65,316 units (SEC Form 4)
Latest SQZ
- SEC Form SC 13G/A filed by SQZ Biotechnologies Company (Amendment)
- SEC Form SC 13G/A filed by SQZ Biotechnologies Company (Amendment)
- SEC Form DEFM14A filed by SQZ Biotechnologies Company
- SEC Form PREM14A filed by SQZ Biotechnologies Company
- SEC Form 15-12G filed by SQZ Biotechnologies Company
- SQZ Biotechnologies Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form EFFECT filed by SQZ Biotechnologies Company
- SEC Form POS AM filed by SQZ Biotechnologies Company
- SEC Form S-8 POS filed by SQZ Biotechnologies Company
- SEC Form 10-Q filed by SQZ Biotechnologies Company